What Is Zenagamtide? Definition and What Research Reports

Zenagamtide is the international non-proprietary style name given to an investigational peptide described in the published literature as a novel unimolecular GLP-1 and amylin receptor agonist — that is, a single engineered molecule designed to activate two distinct receptor systems at once rather than a fixed combination of two separate drugs. It has been evaluated in adults with type 2 diabetes in multicentre, randomised, parallel-group, double-blind, placebo-controlled, dose-finding phase 2 trials of a once-weekly subcutaneous formulation (PMID 42532080) and a once-daily oral formulation (PMID 42532079). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question.

What class of molecule is it?

Zenagamtide belongs to the family of peptide receptor agonists — chains of amino acids engineered to bind and activate specific cell-surface receptors. Two receptor targets are named in the published trial titles:

• The GLP-1 receptor. Glucagon-like peptide-1 is an incretin hormone released from the gut after eating. Peptide agonists at this receptor are a well-established pharmacological class.
• The amylin receptor. Amylin (islet amyloid polypeptide) is co-secreted with insulin from pancreatic beta cells and acts through receptor complexes in the brainstem.

The word unimolecular is the key descriptor in the published titles: rather than co-administering a GLP-1 agonist and an amylin analogue, the two pharmacologies are built into one peptide sequence, so both activities share a single pharmacokinetic profile. Researchers in the field generally use the term "unimolecular co-agonist" (or "dual agonist") for this design, in contrast with "fixed-dose combination", where two chemically separate drugs are given together.

Where the term comes from

The -tide suffix in "zenagamtide" is the standard stem used in non-proprietary drug nomenclature for peptides. The name therefore signals a peptide, not a small molecule, and it is the name used in the clinical trial literature indexed in PubMed. As of the papers listed below, zenagamtide appears in the published record as an investigational compound in phase 2 clinical development; it is not an approved medicine, and there is no approved product label for it.

How the term is used in peptide research

In research writing, "zenagamtide" is used in three broadly consistent ways:

1. As a specific compound name in clinical trial reports — for example, in the phase 2 trial of once-weekly subcutaneous zenagamtide in type 2 diabetes (PMID 42532080).
2. As an example of the GLP-1/amylin co-agonist concept, a design category that researchers discuss alongside other multi-receptor peptides.
3. As the subject of clinical pharmacology studies, such as the study that examined whether renal impairment affected its pharmacokinetics, safety or tolerability (PMID 42443140).

Because the compound is investigational, the literature describes it in the context of controlled trials with defined endpoints and monitoring, not as a product in general use.

What the published literature reports

Three peer-reviewed reports are available in the verified record used for this entry. Their scope is summarised below; details beyond what those publications state are not included here.

Once-weekly subcutaneous administration

A multicentre, randomised, parallel-group, double-blind, placebo-controlled, dose-finding phase 2 trial evaluated the efficacy and safety of once-weekly subcutaneous zenagamtide in people with type 2 diabetes (PMID 42532080). The design features named in that publication — randomisation, parallel groups, double blinding, a placebo comparator and a dose-finding structure — indicate that multiple dose levels were compared against placebo to characterise the dose–response relationship, with both efficacy and safety as declared objectives. Specific numerical outcomes are reported in the full paper rather than summarised here.

Once-daily oral administration

A companion multicentre, randomised, parallel-group, double-blind, placebo-controlled, dose-finding phase 2 trial evaluated once-daily oral zenagamtide in adults with type 2 diabetes (PMID 42532079). The existence of parallel subcutaneous and oral programmes is itself notable: peptides are typically degraded in the gastrointestinal tract, and an oral route for a peptide co-agonist requires formulation work to achieve systemic exposure. Researchers reported on efficacy and safety for this route in the same dose-finding framework used for the injectable form (PMID 42532079).

Clinical pharmacology in renal impairment

A separate study reported that renal impairment did not affect the pharmacokinetics, safety or tolerability of zenagamtide (PMID 42443140). Studies of this kind are a routine part of drug development: they compare how a compound is absorbed, distributed and cleared in participants with varying degrees of kidney function, and they inform whether dosing adjustments would be needed in that population. The conclusion stated in the title of that report was a negative finding — no effect of renal impairment on the parameters examined (PMID 42443140).

Summary of the published record

Safety and Tolerability: What Studies Report

Safety was a declared objective of both phase 2 dose-finding trials, alongside efficacy (PMID 42532080, PMID 42532079). In addition, the clinical pharmacology report stated that renal impairment did not affect safety or tolerability of zenagamtide (PMID 42443140). Specific adverse-event rates, discontinuation figures and dose-level tolerability comparisons are contained in the full texts of those publications; this glossary entry does not reproduce or estimate them. Readers who want the numbers should consult the primary reports directly.

What this entry does not cover

• Doses. This entry states no dose levels, titration schedules or exposure figures, because a glossary stub summarising titles and abstract scope cannot responsibly reproduce them.
• Comparisons with other compounds. The verified literature listed here did not report head-to-head comparisons against other peptide agonists, so none are described.
• Regulatory status beyond the obvious. Zenagamtide appears in the published record as an investigational agent in phase 2 trials; nothing in the cited literature describes marketing approval.
• Outcomes outside type 2 diabetes. The trials cited here enrolled people with type 2 diabetes, and the renal study examined pharmacokinetics; other indications are not addressed in this verified set.

Phase 2 dose-finding trials are, by design, exploratory: they are sized to characterise dose–response and to screen for safety signals, not to establish long-term outcomes. Conclusions about durability, cardiovascular outcomes or comparative effectiveness would require larger and longer studies that are not part of the record summarised here.

References

• Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (Lancet, 2026)
• Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (Lancet, 2026)
• Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide (Diabetes, Obesity & Metabolism, 2026)